{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:19:41Z","timestamp":1793377181045,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.prp.2022.153844","type":"journal-article","created":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T12:51:49Z","timestamp":1647348709000},"page":"153844","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["International Tumor Budding Consensus Conference criteria determine the prognosis of oesophageal adenocarcinoma with poor response to neoadjuvant treatment"],"prefix":"10.1016","volume":"232","author":[{"given":"Philipp","family":"Lohneis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Rohmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Gebauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Hieggelke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Bruns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Schr\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"B\u00fcttner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"L\u00f6ser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Quaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2022.153844_bib1","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1136\/gut.2010.228254","article-title":"Guidelines for the management of oesophageal and gastric cancer","volume":"60","author":"Allum","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.prp.2022.153844_bib2","unstructured":"Leitlinienprogramm Onkologie. S3-Leitlinie \u00d6sophaguskarzinom Langversion 2.0. 2018."},{"key":"10.1016\/j.prp.2022.153844_bib3","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1200\/JCO.2008.17.0506","article-title":"Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction","volume":"27","author":"Stahl","year":"2009","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.prp.2022.153844_bib4","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1002\/ijc.26180","article-title":"Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel","volume":"130","author":"Homann","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.prp.2022.153844_bib5","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/ijc.29403","volume":"137","author":"Schulz","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.prp.2022.153844_bib6","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/S1470-2045(16)30531-9","volume":"17","author":"Al-Batran","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.prp.2022.153844_bib7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2022.153844_bib8","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1097\/SLA.0b013e318216f449","article-title":"Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases","volume":"253","author":"Becker","year":"2011","journal-title":"Ann. Surg."},{"key":"10.1016\/j.prp.2022.153844_bib9","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/SLA.0b013e3182a66588","article-title":"Classification of pathologic response to neoadjuvant therapy in esophageal and junctional cancer: assessment of existing measures and proposal of a novel 3-point standard","volume":"258","author":"Donohoe","year":"2013","journal-title":"Ann. Surg."},{"key":"10.1016\/j.prp.2022.153844_bib10","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1365-2559.2010.03559.x","article-title":"Tumour budding and a low host inflammatory response are associated with a poor prognosis in oesophageal and gastro-oesophageal junction cancers: tumour budding and host inflammatory response in oesophageal cancer","volume":"56","author":"Brown","year":"2010","journal-title":"Histopathology"},{"key":"10.1016\/j.prp.2022.153844_bib11","first-page":"1578","article-title":"Tumor budding is associated with an increased risk of lymph node metastasis and poor prognosis in superficial esophageal adenocarcinoma","volume":"27","author":"Landau","year":"2014","journal-title":"Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc"},{"key":"10.1016\/j.prp.2022.153844_bib12","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00428-020-02897-3","article-title":"Tumor budding assessed according to the criteria of the International Tumor Budding Consensus Conference determines prognosis in resected esophageal adenocarcinoma","volume":"478","author":"Lohneis","year":"2021","journal-title":"Virchows Arch."},{"key":"10.1016\/j.prp.2022.153844_bib13","first-page":"1299","article-title":"Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016","volume":"30","author":"Lugli","year":"2017","journal-title":"Mod. Pathol. . J. U. S. Can. Acad. Pathol. Inc."},{"key":"10.1016\/j.prp.2022.153844_bib14","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/sj.bjc.6602678","article-title":"REporting recommendations for tumour MARKer prognostic studies (REMARK)","volume":"93","author":"McShane","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.prp.2022.153844_bib15","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1093\/annonc\/mdn403","article-title":"Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie","volume":"19","author":"Al-Batran","year":"2008","journal-title":"Ann. Oncol. . J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.prp.2022.153844_bib16","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.prp.2022.153844_bib17","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S1470-2045(11)70142-5","article-title":"Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis","volume":"12","author":"Sjoquist","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.prp.2022.153844_bib18","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2022.153844_bib19","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial","volume":"16","author":"Shapiro","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.prp.2022.153844_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2016.01.016","article-title":"Impact of peritumoral and intratumoral budding in esophageal adenocarcinomas","volume":"52","author":"Thies","year":"2016","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.prp.2022.153844_bib21","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.humpath.2011.07.026","article-title":"Morphology and prognostic value of tumor budding in rectal cancer after neoadjuvant radiotherapy","volume":"43","author":"Du","year":"2012","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.prp.2022.153844_bib22","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00268-011-1409-8","article-title":"Partial pathologic response and nodal status as most significant prognostic factors for advanced rectal cancer treated with preoperative chemoradiotherapy","volume":"36","author":"Huebner","year":"2012","journal-title":"World J. Surg."},{"key":"10.1016\/j.prp.2022.153844_bib23","first-page":"O133","article-title":"The role of epithelial mesenchymal transition and resistance to neoadjuvant therapy in locally advanced rectal cancer","volume":"16","author":"Bhangu","year":"2014","journal-title":"Colorectal Dis. Off. J. Assoc. Coloproctol. G. B. Irel."},{"key":"10.1016\/j.prp.2022.153844_bib24","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/his.12432","article-title":"Pathological prognostic factors in locally advanced rectal carcinoma after neoadjuvant radiochemotherapy: analysis of 113 cases","volume":"65","author":"Sannier","year":"2014","journal-title":"Histopathology"},{"key":"10.1016\/j.prp.2022.153844_bib25","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s00066-018-1340-0","article-title":"The potential predictive value of tumor budding for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer","volume":"194","author":"J\u00e4ger","year":"2018","journal-title":"Strahlenther. Onkol. Organ Dtsch. Rontgengesellschaft Al"},{"key":"10.1016\/j.prp.2022.153844_bib26","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12957-019-1588-6","article-title":"Tumor budding for predicting prognosis of resected rectum cancer after neoadjuvant treatment","volume":"17","author":"Demir","year":"2019","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.prp.2022.153844_bib27","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1186\/s12885-019-6261-5","article-title":"Tumor budding outperforms ypT and ypN classification in predicting outcome of rectal cancer after neoadjuvant chemoradiotherapy","volume":"19","author":"Trotsyuk","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.prp.2022.153844_bib28","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12885-020-6695-9","article-title":"High tumor budding is a strong predictor of poor prognosis in the resected perihilar cholangiocarcinoma patients regardless of neoadjuvant therapy, showing survival similar to those without resection","volume":"20","author":"Ito","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.prp.2022.153844_bib29","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1002\/cncr.24390","article-title":"Tumor budding in tumor invasive front predicts prognosis and survival of patients with esophageal squamous cell carcinomas receiving neoadjuvant chemotherapy","volume":"115","author":"Miyata","year":"2009","journal-title":"Cancer"}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033822000875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033822000875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T06:51:44Z","timestamp":1759733504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033822000875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":29,"alternative-id":["S0344033822000875"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2022.153844","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"International Tumor Budding Consensus Conference criteria determine the prognosis of oesophageal adenocarcinoma with poor response to neoadjuvant treatment","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2022.153844","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"153844"}}